Exploring the versatile roles of the endocannabinoid system and phytocannabinoids in modulating bacterial infections
Open Access
- 11 June 2024
- journal article
- review article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 92 (6) , e0002024
Abstract
The endocannabinoid system (ECS), initially identified for its role in maintaining homeostasis, particularly in regulating brain function, has evolved into a complex orchestrator influencing various physiological processes beyond its original association with the nervous system. Notably, an expanding body of evidence emphasizes the ECS’s crucial involvement in regulating immune responses. While the specific role of the ECS in bacterial infections remains under ongoing investigation, compelling indications suggest its active participation in host-pathogen interactions. Incorporating the ECS into the framework of bacterial pathogen infections introduces a layer of complexity to our understanding of its functions. While some studies propose the potential of cannabinoids to modulate bacterial function and immune responses, the outcomes inherently hinge on the specific infection and cannabinoid under consideration. Moreover, the bidirectional relationship between the ECS and the gut microbiota underscores the intricate interplay among diverse physiological processes. The ECS extends its influence far beyond its initial discovery, emerging as a promising therapeutic target across a spectrum of medical conditions, encompassing bacterial infections, dysbiosis, and sepsis. This review comprehensively explores the complex roles of the ECS in the modulation of bacteria, the host’s response to bacterial infections, and the dynamics of the microbiome. Special emphasis is placed on the roles of cannabinoid receptor types 1 and 2, whose signaling intricately influences immune cell function in microbe-host interactions.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01 AI158749-02)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (5T32AI007110-38)
- Consortium for Medical Marijuana Clinical Outcomes Research
This publication has 179 references indexed in Scilit:
- Cannabinoid receptor 2 activation decreases severity of cyclophosphamide‐induced cystitis via regulating autophagyNeurourology and Urodynamics, 2019
- Cannabidiol prevents LPS‐induced microglial inflammation by inhibiting ROS/NF‐κB‐dependent signaling and glucose consumptionGlia, 2019
- Molecular Mechanism and Cannabinoid Pharmacology2019
- Cannabinoid receptor 1 but not 2 mediates macrophage phagocytosis by G(α)i/o/RhoA/ROCK signaling pathwayJournal of Cellular Physiology, 2014
- Endocannabinoids and energy homeostasis: An updateBioFactors, 2014
- Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in miceHepatology, 2011
- Anandamide and 2-Arachidonoylglycerol Inhibit Fatty Acid Amide Hydrolase by Activating the Lipoxygenase Pathway of the Arachidonate CascadeBiochemical and Biophysical Research Communications, 2000
- A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suisJournal of Leukocyte Biology, 2000
- 2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in BrainBiochemical and Biophysical Research Communications, 1995
- Antibacterial activity of Δ9-tetrahydrocannabinol and cannabidiolAntonie van Leeuwenhoek, 1976